Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
DFRF4539A · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Single Arm | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| DFRF4539A | DRUG | multiple ascending doses |
Inclusion Criteria: * Adult patients; \>/= 18 years of age * Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2 * Relapsed or refractory multiple myeloma for which no effective standard therapy exists * One of the prior therapies must have included a proteosome inhibitor or an ...
Top 20 of 25 competitors
DFRF4539A is an investigational small molecule being studied for the treatment of multiple myeloma. It is being developed by Roche Holding AG (RHHBY). The drug is currently in Phase 1 clinical development, meaning it is still being tested in clinical trials and is not yet approved for use.
DFRF4539A is being developed by Roche Holding AG, which trades under the ticker RHHBY. The company is conducting clinical research on this investigational drug for multiple myeloma. As of now, DFRF4539A is in Phase 1 development and has not been approved by regulatory authorities.
DFRF4539A is in Phase 1 clinical development. It is an investigational drug for multiple myeloma and has not yet been approved. The Phase 1 trial has been completed, and the drug remains in early-stage clinical testing.
DFRF4539A has been studied in one clinical trial, identified as NCT01432353. This was a Phase 1 study in patients with relapsed or refractory multiple myeloma. The trial was conducted in the United States and enrolled 39 participants. The study has been completed.
DFRF4539A is not FDA approved. It is an investigational drug currently in Phase 1 clinical development for multiple myeloma. The drug is being studied in clinical trials to evaluate its safety and efficacy, but it has not yet received regulatory approval.